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Abstract 26 
We have assessed whether HLA immunogenicity as defined by differences in donor-27 recipient HLA amino-acid sequence (amino-acid mismatch score, AMS; and eplet 28 mismatch score, EpMS) and physicochemical properties (electrostatic mismatch 29 score, EMS) enables prediction of allosensitisation to HLA, and also prediction of the 30 risk of an individual donor-recipient HLA mismatch to induce donor-specific 31 antibody (DSA). HLA antibody screening was undertaken using single-antigen beads 32 in 131 kidney transplant recipients returning to the transplant waiting list following 33 first graft failure. The effect of AMS, EpMS and EMS on the development of 34 allosensitisation (calculated reaction frequency, cRF) and DSA was determined. 35 Multivariate analyses, adjusting for time on the waiting list, maintenance on 36 immunosuppression after transplant failure and graft nephrectomy, showed that 37 AMS (OR: 1.44 per 10 units, 95% CI: 1.02-2.10, p=0.04) and EMS (OR: 1.27 per 10 38 units, 95% CI: 1.02-1.62, p=0.04) were independently associated with the risk of 39 developing sensitisation to HLA (cRF>15%). AMS, EpMS and EMS were 40 independently associated with the development of HLA-DR and HLA-DQ DSA, but 41 only EMS correlated with the risk of HLA-A and -B DSA development. Differences in 42 donor-recipient HLA amino-acid sequence and physicochemical properties enable 43 better assessment of the risk of HLA-specific sensitisation than conventional HLA 44 matching. 45 
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Introduction 47 
Many countries operate deceased donor kidney allocation schemes that aim to 48 ensure equity of access to transplantation, while minimising the number of donor 49 HLA mismatches to reduce the risk of graft rejection. The diversity of HLA types is 50 such that while poorly HLA matched grafts can usually be avoided, most (>80%) 51 recipients receive grafts with one or more HLA mismatches. Inevitably, many grafts 52 eventually fail and this is often associated with the development of antibodies 53 against mismatched donor HLA. If repeat transplantation is undertaken it is usually 54 necessary to avoid donor HLA mismatches against which the patient is sensitised, a 55 requirement that markedly limits access to transplantation. 56 
It was generally assumed that the breadth of sensitisation following a failed 57 transplant increased with the number of donor HLA mismatches, although the 58 precise relationship had not been examined.  We recently showed that the risk of 59 allosensitisation following failure of a first renal transplant increases incrementally 60 with the number of mismatches at individual HLA-A, -B, -C, -DR and -DQ loci (1). In 61 this study, mismatches were based on HLA specificities and the number of donor 62 mismatches within each locus was enumerated as 0, 1 or 2. However, all HLA 63 mismatches within a given locus were considered to have equal relevance to 64 allosensitisation and no account was taken of potential differences in 65 immunogenicity according to donor HLA mismatch and recipient HLA type. 66 
Recent studies, by our group (2-4) and others (5-8), have shown that HLA 67 alloantigen immunogenicity can be more accurately assessed by evaluating 68 
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differences in the number and location of amino acid (AA) mismatches at 69 continuous and discontinuous (eplet) positions, as well as their physicochemical 70 properties. In these approaches, inter-locus (HLA-A, -B, -C or HLA-DRB1/3/4/5) or 71 intra-locus (HLA-DQA1/DQB1) AA sequence subtraction is performed on the 72 assumption that a polymorphic AA residue at a given sequence position within a 73 donor HLA can be considered non-immunogenic if it is expressed on the recipient 74 HLA molecules. In the present study we sought to determine whether donor HLA 75 immunogenicity as defined by differences in the number of amino acid mismatches 76 as well as their physicochemical properties enables better prediction of the 77 development of HLA-specific antibodies in patients listed for repeat renal 78 transplantation. 79 
  80 
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Methods 81 
Patients and HLA-specific antibody screening 82 
The patient population studied and the antibody screening protocol used have been 83 described in detail previously (1). Briefly, the study cohort comprised 131 84 consecutive patients (87 males, 44 females, median age 38) who received a primary 85 kidney allograft between 1995 and 2010, and returned to the Cambridge kidney 86 transplant waiting list following failure of their graft during this time period [56 87 patients (43%) underwent transplant nephrectomy]. Of the 131 patients, 66 88 (50.4%) continued to receive immunosuppression after return to the waiting list 89 [36 patients received a single agent (prednisolone in all but 4 patients) and 30 90 received multiple immunosuppressive agents (mostly a CNI inhibitor and 91 prednisolone)].  During the period when recipients received their primary kidney 92 transplant, organ allocation favoured HLA matching, particularly at the HLA-DR 93 locus. Whereas only 11% of the recipient cohort received a donor kidney transplant 94 with 0-1 HLA-A, -B and -C mismatches, 49% received a graft with 0-1 HLA-DR 95 mismatch. Antibody screening was undertaken at the time of (and prior to) the first 96 transplant, after return to the transplant waiting list following graft failure and at 3 97 monthly intervals while remaining on the list for re-transplantation. Screening was 98 undertaken using Luminex single antigen beads with MFI cut-off thresholds of 2000 99 and 8000 to identify the presence of donor specific antibodies (DSA) and to allow 100 determination of the calculated reaction frequency (cRF) against a panel of 10,000 101 consecutive UK organ donors (9). For each patient, cRF was determined for HLA 102 class I loci (HLA-A, -B, -C), for HLA class II loci (HLA-DRB1/3/4/5 and HLA-DQ), and 103 
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for HLA class I and II loci combined. Multiple sera for each patient listed for re-104 transplantation were examined and the peak reactive serum was identified as that 105 showing the highest cRF within a median (SD) follow-up period since first 106 transplantation of 2539 (1605) days. Patient sera may exhibit high reactivity to HLA 107 (high cRF) due to the presence of multiple alloantibodies or due to a limited number 108 of alloantibodies directed against broadly reactive public epitopes; such analyses 109 were beyond the scope of this study. 110 
Determination of HLA amino acid mismatch score (AMS), electrostatic 111 
mismatch score (EMS) and eplet mismatch score (EpMS) 112 
The amino acid mismatch score (AMS) for each mismatched donor HLA was 113 determined by performing inter- and intra-locus amino acid sequence comparisons 114 between the donor HLA and the recipient HLA class I or class II type using a 115 previously described computer algorithm (3, 4). Similarly, the electrostatic 116 mismatch score (EMS) for each mismatched donor HLA was calculated as the sum of 117 the differences in isoelectric point for each mismatched amino acid [identified 118 above, (3, 4)]. For each patient, the total AMS and the total EMS were calculated by 119 summing the AMS or the EMS for each mismatched HLA present on the kidney 120 donor HLA type. The computer algorithm is freely available for download 121 (http://www.hlaimmunogenicity.org/download/Cambridge_HLA_Class_I_Immunog122 enicity_Algorithm.xls and http://www.hlaimmunogenicity.org/download/ 123 Cambridge_HLA_Class_II_Immunogenicity_Algorithm.xls). 124 
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The eplet mismatch score (EpMS) between kidney donor and recipient HLA class I 125 and class II types was determined using the HLAMatchmakerTM computer algorithm 126 (6, 8). 127 
Statistical methods 128 
Study population characteristics and descriptive statistics for this patient cohort 129 have been detailed previously (1). A univariate exploratory analysis incorporating 130 HLA immunogenicity variables was performed and is presented in supplementary 131 Table 1. Logistic regression was used to perform univariate and multivariate 132 analyses to explore the association of conventional HLA mismatch grade, HLA 133 immunogenicity scores and clinical variables, with the risk of developing post-134 transplant failure HLA-specific sensitisation (cRF>15%) and with the risk of 135 becoming highly-sensitised (cRF≥85%). To examine for an independent effect of 136 HLA immunogenicity scores on post-transplant sensitisation, adjusting for the effect 137 of conventional HLA mismatch grade, and to account for potential collinearity 138 between these variables, linear regression was used to de-correlate AMS, EpMS or 139 EMS from HLA mismatch grade before inclusion into the models. The p-values were 140 taken from likelihood ratio tests. For the donor-specific antibody analyses (DSA), 141 logistic regression models were used to investigate the association between the 142 development of DSA responses (at MFI levels of >2000 and >8000) and clinical and 143 HLA immunogenicity explanatory variables. Initially, each explanatory variable was 144 modelled separately; further models investigated the additional value in 145 incorporating AMS, EpMS or EMS into models including dual immunosuppression 146 while on the waiting list, length of time on the waiting list, and allograft 147 
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nephrectomy (DSA analyses consider individual donor-recipient HLA mismatches 148 and, therefore, correction for conventional HLA match grade is not applicable). For 149 presentation, AMS, EpMS and EMS were grouped, but for regression models, the 150 absolute value was used. Statistical significance was assessed using likelihood ratio 151 tests at 5% significance level. Due to the inherent correlation between HLA 152 immunogenicity scores, AMS, EpMS or EMS were included separately into the 153 multivariate models. All analyses were performed in R (R Foundation for Statistical 154 Computing, Vienna, Austria)(10).  155 
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Results 156 
Antibody screening of the 131 patients comprising the study cohort showed that 157 before transplantation, 16.0% of patients were sensitised (cRF>15%) and 3.8% 158 were highly sensitised (cRF≥85%) to HLA. While on the waiting list for repeat 159 kidney transplantation, 67.9% became sensitised and 49.6% became highly 160 sensitised to HLA. As reported previously, the level of sensitisation in this cohort 161 increased incrementally with the number of donor HLA mismatches of their failed 162 transplant, and all HLA loci assessed (HLA-A, -B, -C, -DRB1, -DRB3/4/5, and DQB1) 163 contributed independently to sensitisation (adjusted for pre-transplant 164 sensitisation), although the contribution of HLA-C locus mismatches was less 165 pronounced. Sensitisation was also independently associated with length of time on 166 the waiting list for repeat transplantation and with maintenance of dual therapy 167 immunosuppression (1).  168 
In the present study we examined the association between HLA-specific antibody 169 formation and the immunogenicity of donor HLA mismatches as determined by the 170 amino acids mismatch score (AMS), eplet mismatch score (EpMS) and the 171 electrostatic mismatch score (EMS) between donor and recipient HLA molecules. 172 The mean (SD) AMS, EpMS and EMS for HLA class I was 20 (11.1), 17 (9.4) and 31 173 (20.8) respectively; the mean (SD) AMS, EpMS and EMS for HLA-DR (-DRB1 and -174 DRB3/4/5) was 5 (7.2), 8 (10.0) and 7 (9.3) respectively; and the mean (SD) AMS, 175 EpMS and EMS for HLA-DQ (-DQA1 and -DQB1) was 11 (15.4), 12 (13.9) and 15 176 (22.8) respectively. 177 
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Influence of donor HLA immunogenicity on development of post-transplant 178 
HLA-specific sensitisation (expressed as calculated reaction frequency) 179 
An exploratory univariate analysis was undertaken to determine if the 180 immunogenicity of donor HLA mismatches expressed by the failed kidney 181 transplant, as assessed by AMS, EpMS, and EMS, was associated with subsequent 182 sensitisation detected on analysis of peak reactive sera while patients were on the 183 list for repeat transplantation. For this analysis, cRF levels were categorised into 4 184 bands (0-15%, 16-50%, 51-84% and 85-100%). As shown in Figure 1, sensitisation 185 to HLA class I, HLA class II, and overall HLA class I and class II increased with 186 increasing AMS (OR on overall cRF>15%: 1.40, 95% CI: 1.16-1.71 per 10 unit 187 increase of AMS, p<0.001), EpMS (OR on overall cRF>15%: 1.36, 95% CI: 1.13-1.64 188 per 10 unit increase of EpMS, p<0.001) or EMS (OR on overall cRF>15%: 1.27, 95% 189 CI: 1.11-1.45 per 10 unit increase of EMS, p<0.001). 190 
Subsequently, multivariate logistic regression was used to adjust for the effect on 191 sensitisation of the length of time on the waiting list and of maintenance of dual 192 therapy immunosuppression while on the waiting list for re-transplantation. The 193 analysis was also controlled for the inherent correlation between conventional HLA 194 mismatch grade (0, 1 or 2 HLA mismatches per locus) and HLA immunogenicity 195 scores, using linear regression to de-correlate the AMS, EpMS or EMS from the 196 number of donor HLA mismatches present on the failed kidney transplant. As shown 197 in Table 1, donor HLA immunogenicity as assessed by AMM, EpMS and EMS was 198 independently associated with the risk of developing post-transplant HLA class I 199 and class II specific antibodies (cRF 16-100%), providing additional predictive value 200 
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to that of conventional HLA mismatch grade. HLA mismatch grade (OR: 1.29, 95% 201 CI: 1.07-1.59, p=0.01), dual agent immunosuppression (OR: 0.28, 95% CI: 0.08-0.81, 202 p=0.03) and time on the waiting list (OR: 1.35, 95% CI: 1.13-1.67, p=0.002) were all 203 associated with the risk of a patient becoming highly sensitised (cRF≥85%), 204 whereas AMM, EpMS and EMS had no independent effect. 205 
We also examined the effect of donor HLA immunogenicity scores on the risk of 206 developing sensitisation to HLA-A, -B, -C; HLA-DR (-DRB1 and -DRB3/4/5); and 207 HLA-DQ. Multivariate analyses showed that AMS, EpMS and EMS were 208 independently associated with the risk of developing HLA class I (cRF>15% and 209 
cRF≥85%) and HLA-DQ specific antibodies (cRF>15%), whereas HLA-DR mismatch 210 grade correlated with locus-specific sensitisation with an additional effect 211 attributable to HLA-DR EMS for high (≥85%) HLA-DR specific cRF (supplementary 212 Table 2). 213 
Influence of donor HLA immunogenicity on development of post-transplant 214 
donor-specific antibodies (DSA) 215 
We next sought to determine the factors associated with the development of donor 216 specific antibodies (DSA) against the HLA mismatches present on the failed renal 217 allograft. For this analysis, all donor-recipient HLA mismatches for the entire study 218 cohort (n=671) were pooled and analysed together. While on the waiting list for re-219 transplantation, 40 patients developed DSA against HLA class I, 4 against HLA class 220 II and 31 against both HLA class I and II. Overall, DSA was detected against 235 of 221 the 671 (35%) donor-recipient HLA mismatches with a median (SD) MFI of 8071 222 
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(5129). Donor specific antibody responses against HLA-C mismatches were 223 infrequent (16.8%) and not associated with donor HLA-C alloantigen 224 immunogenicity. Univariate logistic regression analysis (Figure 2A) focusing on 225 HLA-A and -B DSA responses showed that the EMS, but not AMS or EpMS, of a donor 226 HLA correlated with the likelihood of an antibody response. Multivariate analyses, 227 adjusting for length of time on the waiting list, maintenance on dual therapy 228 immunosuppression, and for nephrectomy, confirmed that EMS was independently 229 associated with HLA-A and -B DSA development (for DSA MFI>2000, OR: 1.81, 95% 230 CI: 1.16-2.86, p= 0.01 per 10 EMS units; and for DSA MFI>8000, OR: 1.62, 95% CI: 231 1.01-2.59, p=0.04 per 10 EMS units; Table 2). Multivariate logistic regression 232 analyses of HLA Class II DSA responses showed that all three HLA immunogenicity 233 scores were independently associated with the development of HLA-DR (at 234 MFI>2000 and >8000) and HLA-DQ DSA (Table 2 and Figure 2B and 2C) and no 235 differences in the predictive power of AMS, EpMS or EMS were observed. 236 
Discussion 237 
The risk of allosensitisation following failure of a first renal transplant increases 238 incrementally with the number of mismatches at individual HLA-A, -B, -C, -DR and -239 DQ loci (1). However, this simple numerical approach to assessing HLA mismatch 240 grade takes no account of differences in donor HLA immunogenicity according to 241 recipient HLA type and this is likely to have an important influence on the 242 alloimmune response. Knowledge of HLA structure, along with the ability to 243 characterise alloantibody specificities in patient sera using single antigen bead 244 technology, now allows the potential impact of differences between donor and 245 
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recipient HLA molecules to be determined, with a view to developing improved 246 strategies for kidney allocation.  247 
In the present study we examined three different approaches for assessment of HLA 248 class I and class II immunogenicity. These ranged from simply enumerating the 249 number of mismatched amino acids (AMM) between donor and recipient HLA, to 250 counting the number of polymorphic surface accessible amino acid residues at 251 discontinuous positions of donor HLA that cluster together to form a potential 252 epitope (EpMS), to assessing the physicochemical disparity between the side chains 253 of mismatched amino acids between donor and recipient HLA (EMS). The principal 254 finding was that assessment of donor HLA immunogenicity based on AMS, EpMS or 255 EMS offers additional value to that of conventional HLA mismatch grade for 256 predicting sensitisation to HLA in patients awaiting re-transplantation after a failed 257 first kidney transplant. Moreover, donor HLA-DR and -DQ alloantigens with high 258 AMS, EpMS or EMS were more likely to induce DSA responses, which in the case of 259 HLA-DR were more likely to be of high level (MFI>8000). Importantly, donor HLA 260 EMS, but not AMS or EpMS, predicted the development of DSA (at MFI>2000 and 261 >8000) against HLA-A and -B mismatches. 262 
Following kidney transplantation, donor specific antibody development against 263 both HLA class I and class II alloantigens is an important risk factor for subsequent 264 chronic humoral rejection and allograft failure (11-14). Humoral responses against 265 HLA class II are frequent and commonly involve HLA-DQ specific antibodies (15, 266 16). Our study suggests that the risk of developing both HLA-DR and -DQ DSA can be 267 predicted by accounting for the immunogenicity of donor HLA class II mismatches. 268 
15  
Our findings agree with recent reports from Wiebe et al demonstrating that high 269 donor HLA-DR and -DQ immunogenicity, as assessed by high epitope (eplet) load, 270 increases the risk of DSA development and of subsequent kidney graft failure (17, 271 18). We did not, however, demonstrate an advantage in using an eplet approach to 272 assess HLA immunogenicity over simply enumerating the number of amino acid 273 polymorphisms between donor and recipient HLA molecules. AMS and EpMS both 274 reflect differences in amino acid sequence between donor and recipient HLA 275 mismatches and while aiding prediction of immunogenicity of a particular HLA 276 mismatch, they do not take account of the physicochemical properties of the amino 277 acid polymorphisms involved. The specificity and affinity of antibody binding to 278 target antigen is strongly influenced by electrostatic interactions and these are 279 determined by the number and polar charges of amino acid side chains (2, 19). EMS 280 integrates information on the number of mismatched amino acids and the 281 differences in electrostatic charges of their side chains between donor and recipient 282 HLA class I and class II molecules. Our results show that this additional information 283 improves the ability to predict the development of an alloantibody response against 284 a given HLA mismatch. 285 
While the present study clearly shows that prediction of HLA immunogenicity based 286 on information derived from polymorphic amino acids on donor HLA and their 287 physicochemical properties is superior to the traditional approach of assigning 288 equal weight to all HLA mismatches within a particular locus, there are some 289 limitations to our study. First, we analysed alloantibody responses after kidney 290 transplant failure and our findings would be strengthened if they were confirmed in 291 
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patients with functioning grafts. This would require access to data from a 292 prospective post-transplant alloantibody monitoring programme with long-term 293 follow up which is not currently widely available. Second, our analysis is 294 strengthened by quantitative analyses of DSA development based on MFI cut off 295 levels of >2000 and >8000. However, even though we routinely treat sera with 296 EDTA to overcome the prozone phenomenon (20, 21), we acknowledge that 297 titration studies would have provided further evidence on alloantibody strength 298 (22). Moreover, HLA-DP type was not routinely performed during the period of the 299 study so we were unable to consider its influence on allosensitisation, and it is 300 apparent that many patients become sensitised to HLA-DP after transplant failure 301 (23). There is, however, no a priori reason why amino acid comparison after intra-302 locus subtraction for HLA-DP should not predict allosensitisation since HLA-DP is 303 structurally very similar to HLA-DR and -DQ (24). As described previously (1), the 304 patient cohort in the present study were moderately well-matched particularly for 305 HLA-DR and -DQ. While the size of the study cohort was sufficient to demonstrate 306 the additional influence of AMS, EpMS and EMS over simply counting mismatched 307 HLA specificities, it did not allow in depth analysis of HLA-DQ immunogenicity, 308 because of the limited number of mismatched HLA-DQ specificities within the study 309 cohort. Finally, we have previously shown that transplant nephrectomy did not have 310 an independent effect on overall sensitisation to HLA when withdrawal of 311 immunosuppression was taken into account (1). However, the present study 312 showed that transplant nephrectomy was independently associated with DSA 313 development against donor HLA-A and -B alloantigens suggesting that these 314 
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alloantibodies may be absorbed to an extent by the graft and become more apparent 315 after its removal. A similar effect for DSA against HLA class II was not demonstrated 316 and, as explained above, this may be due to the relatively limited number of HLA 317 class II mismatches in this patient cohort. 318 
In conclusion, our findings demonstrate a clear relationship between the 319 immunogenicity of donor HLA class I and class II mismatches and the development 320 of HLA-specific antibodies after graft failure and relisting for transplantation. HLA 321 antibodies severely limit the chance of finding an antibody-compatible donor kidney 322 for patients requiring re-transplantation and HLA matching is, therefore, 323 particularly important in recipients who are likely to require repeat transplantation 324 in the future. While the traditional approach to HLA matching, based on counting 325 the number of mismatched HLA specificities has merit, our findings show that more 326 sophisticated approaches to determining HLA compatibility improve assessment of 327 HLA immunogenicity and consideration should be given to incorporating them into 328 HLA matching algorithms. Eurotransplant have implemented the use of 329 HLAMatchmaker to identify antibody compatible donors for patients who are 330 already highly sensitised (25, 26). The present study supports the incorporation of 331 such approaches to HLA matching for allocation of deceased donor kidneys to first-332 time recipients. Although further validation is required, our findings suggest that 333 information on the electrostatic charge of polymorphic amino acids in mismatched 334 HLA alleles (EMS) should be introduced into HLA matching algorithms, as it 335 improves prediction of donor-specific antibody development and HLA-specific 336 sensitisation. Such approaches to HLA matching are also more permissive than 337 
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simply aiming to avoid as many HLA mismatches as possible, because they identify 338 acceptable HLA mismatches that are likely to be of low immunogenicity, thereby 339 increasing the number of deceased donors that might be considered a suitable HLA 340 match for a given recipient. 341 
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Figure Legends 357 
Figure 1. Association between the immunogenicity of first transplant donor 358 
HLA mismatches and post-transplant HLA-specific sensitisation expressed as 359 
calculated reaction frequency (cRF). 360 
HLA-specific alloantibodies were detected using single-antigen HLA beads [mean 361 fluorescence intensity (MFI) cut-off threshold of 2000]; the likelihood of identifying 362 an antibody-compatible organ donor (cRF) was determined by comparing 363 individual patient HLA-specific antibody profiles with the HLA types of 10,000 364 consecutive UK deceased organ donors. Panel (A) shows peak cRF levels while on 365 the waiting list attributable to antibodies against HLA-A, -B, and -C considered 366 collectively according to the immunogenicity of donor HLA class I mismatches 367 expressed by the failed kidney transplant, as assessed by amino acid mismatch score 368 (AMS), eplet mismatch score (EpMS), and electrostatic mismatch score (EMS). Panel 369 (B) shows peak cRF levels while on the waiting list attributable to antibodies against 370 HLA-DRB1, -DRB3/4/5 and -DQ, considered collectively according to the 371 immunogenicity of donor HLA class II mismatches present on the failed kidney 372 transplant, as assessed by AMS, EpMS and EMS. Panel (C) shows peak cRF levels 373 while on the waiting list attributable to antibodies against HLA class I and class II 374 considered collectively according to the immunogenicity of donor HLA class I and 375 class II mismatches present on the failed kidney transplant, as assessed by AMS, 376 EpMS and EMS. Patients were categorized according to the likelihood of identifying 377 an antibody-compatible organ donor as cRF 0–15%, cRF 16–50%, cRF 51–84%, and 378 
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cRF 85–100%. Patients were grouped in quantiles of the variable of interest (AMS, 379 EpMS or EMS) and within each group the number of patients is shown. 380 
Figure 2. Logistic regression analyses of the relationship between the 381 
immunogenicity of donor HLA mismatches and development of post-382 
transplant donor-specific antibodies (DSA). 383 
Development of alloantibodies against donor HLA mismatches expressed by the 384 failed kidney transplant were detected using single-antigen HLA bead analysis of 385 sera obtained following transplant failure [using mean fluorescence intensity (MFI) 386 cut-off thresholds of 2000 and 8000 to reflect increasing levels of DSA]. Panels (A), 387 (B) and (C) show the fitted logistic regression curves (green line for DSA with 388 MFI>2000 and red line for DSA with MFI>8000) for HLA-A and -B; HLA-389 DRB1/3/4/5; and HLA-DQ DSA respectively. For the regression models absolute 390 values were used, but for presentation AMS, EpMS and EMS were grouped and the 391 number of DSA and MFI levels within each group is shown. 392 
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Table 1. Multivariate analysis: influence of donor HLA immunogenicity on the 491 
development of post-transplant HLA class I and class II specific antibodies 492 
(expressed as calculated reaction frequency - cRF) 493 
Variable Odds ratio (95% CI) on developing HLA-specific sensitisation (cRF 16-100%) Odds ratio (95% CI) on becoming highly sensitised (cRF 85-100%)  OR (95% CI) p-value OR (95% CI) p-value AMS (per 10 AA MM)* 1.44 (1.02, 2.10) 0.04 1.22 (0.91, 1.65) 0.18 HLA (per MM) 1.29 (1.05, 1.62) 0.02 1.29 (1.07, 1.59) 0.01 Dual agent immunosuppression 0.42 (0.16, 1.11) 0.08 0.28 (0.08, 0.81) 0.03 Time on the waiting list (per year) 1.54 (1.21, 2.07) 0.001 1.35 (1.13, 1.67) 0.002 
 EpMS (per 10 eplet MM)* 1.41 (1.00, 2.05) 0.05 1.26 (0.94, 1.71) 0.13 HLA (per MM) 1.39 (1.05, 1.63) 0.02 1.30 (1.07, 1.59) 0.01 Dual agent immunosuppression 0.39 (0.15, 1.04) 0.06 0.26 (0.08, 0.77) 0.02 Time on the waiting list (per year) 1.51 (1.19, 2.01) 0.002 1.34 (1.11, 1.65) 0.003 
 EMS (per 10 units)* 1.27 (1.02, 1.62) 0.04 1.13 (0.94, 1.37) 0.20 HLA (per MM) 1.30 (1.05, 1.64) 0.02 1.30 (1.07, 1.59) 0.01 Dual agent immunosuppression 0.40 (0.15, 1.04) 0.06 0.27 (0.08, 0.77) 0.02 Time on the waiting list (per year) 1.54 (1.19, 2.07) 0.002 1.34 (1.11, 1.65) 0.003 MM: mismatches 494 A minority of this patient cohort had low level HLA-specific sensitisation before 495 transplantation; adjustment for pre-transplant sensitisation levels was performed and did 496 not change significantly the results of these analyses. 497 *Linear regression was used to de-correlate AMS, EpMS or EMS from HLA mismatch grade 498 before inclusion into the multivariate models.  499 
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Table 2. Multivariate analysis: influence of donor HLA immunogenicity on 500 
development of post-transplant donor-specific antibodies (DSA) 501 
Variable Odds ratio (95% CI) on developing HLA donor-specific antibodies (MFI>2000) 
Odds ratio (95% CI) on developing high level HLA donor-specific antibodies (MFI>8000) 
HLA-A and -B OR (95% CI) p-value OR (95% CI) p-value AMS (per 10 AA MM) 2.02 (1.01, 4.12) 0.05 1.72 (0.81, 3.65) 0.16 Dual agent immunosuppression 0.36 (0.14, 0.83) 0.02 0.29 (0.09, 0.79) 0.02 Time on the waiting list (per year) 1.31 (1.16, 1.48) <0.001 1.02 (0.90, 1.15) 0.75 Nephrectomy 2.27 (1.27, 4.15) 0.006 1.19 (0.64, 2.26) 0.59 
 EpMS (per 10 eplet MM) 2.04 (0.90, 4.69) 0.09 1.44 (0.59, 3.46) 0.42 Dual agent immunosuppression 0.35 (0.14, 0.82) 0.02 0.29 (0.09, 0.79) 0.02 Time on the waiting list (per year) 1.30 (1.15, 1.47) <0.001 1.01 (0.90, 1.14) 0.81 Nephrectomy 2.20 (1.23, 4.02) 0.009 1.17 (0.63, 2.22) 0.62 
 EMS (per 10 units) 1.81 (1.16, 2.86) 0.01 1.62 (1.01, 2.59) 0.04 Dual agent immunosuppression 0.34 (0.13, 0.80) 0.02 0.28 (0.09, 0.76) 0.02 Time on the waiting list (year) 1.29 (1.15, 1.47) <0.001 1.00 (0.90, 1.14) 0.87 Nephrectomy 2.15 (1.20, 3.95) 0.01 1.13 (0.60, 2.15) 0.71  
HLA-DRB1/3/4/5 OR (95% CI) p-value OR (95% CI) p-value AMS (per 10 AA MM) 5.42 (2.23, 15.01) <0.001 4.02 (1.65, 10.94) 0.003 Dual agent immunosuppression 0.05 (0.01, 0.21) <0.001 N/A* - Time on the waiting list (per year) 1.00 (0.83, 1.19) 0.96 0.93 (0.75, 1.15) 0.53  
27  
EpMS (per 10 eplet MM) 6.30 (2.30, 19.30) <0.001 6.97 (2.24, 25.58) 0.002 Dual agent immunosuppression 0.06 (0.01, 0.23) <0.001 N/A* - Time on the waiting list (per year) 0.98 (0.82, 1.17) 0.83 0.93 (0.75, 1.16) 0.54  EMS (per 10 units) 2.77 (1.52, 5.52) 0.002 2.37 (1.32, 4.68) 0.006 Dual agent immunosuppression 0.06 (0.01, 0.24) <0.001 N/A* - Time on the waiting list (per year) 0.94 (0.79, 1.11) 0.50 0.89 (0.72, 1.09) 0.28  
HLA-DQ OR (95% CI) p-value OR (95% CI) p-value AMS (per 10 AA MM) 1.79 (1.19, 2.71) 0.005 1.49 (0.92, 2.47) 0.11 Dual agent immunosuppression 0.18 (0.01, 1.10) 0.12 0.29 (0.01, 1.93) 0.28 Time on the waiting list (per year) 0.91 (0.70, 1.15) 0.43 0.82 (0.58, 1.09) 0.20  EpMS (per 10 eplet MM) 1.99 (1.20, 3.47) 0.011 1.59 (0.86, 3.08) 0.15 Dual agent immunosuppression 0.17 (0.01, 1.00) 0.10 0.28 (0.01,1.78) 0.25 Time on the waiting list (per year) 0.91 (0.71, 1.15) 0.45 0.82 (0.58, 1.10) 0.21  EMS (per 10 units) 1.46 (1.14, 1.90) 0.003 1.26 (0.93, 1.70) 0.14 Dual agent immunosuppression 0.17 (0.01, 1.01) 0.11 0.27 (0.01, 1.72) 0.24 Time on the waiting list (per year) 0.89 (0.69, 1.14) 0.37 0.81 (0.57, 1.09) 0.20 *HLA-DR DSA in patients on dual agent immunosuppression had MFI values below 8000. 502 


